PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc. (PMVP) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PMVP · as of Sep 30, 2025
Ownership Breakdown
63
Institutional Holders
▲ 10 vs Q2
$52.49M
Total Inst. Value
▲ $15.73M vs Q2
53.33M
Shares Outstanding
freeFloat 91.68%
37.49M
13F Shares Held
▲ 2.81M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PMVP largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ORBIMED ADVISORS LLC pharmaceutical preparations | 5.98M | 11.49% | 11.49% | $8.37B | Nov 14, 2025 | ▼ 500.0K |
BML CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 5.29M | 10.17% | 10.17% | $7.41B | Nov 10, 2025 | ▲ 292.0K |
TANG CAPITAL MANAGEMENT LLC pharmaceutical preparations | 4.79M | 9.20% | 9.20% | $6.70B | Nov 14, 2025 | NEW |
ARROWMARK COLORADO HOLDINGS LLC pharmaceutical preparations | 3.30M | 6.35% | 6.35% | $4.62B | Nov 14, 2025 | ▲ 113.2K |
SIO CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 2.64M | 5.07% | 5.07% | $3.69B | Nov 13, 2025 | ▼ 1.10M |
EUCLIDEAN CAPITAL LLC pharmaceutical preparations | 2.63M | 5.05% | 5.05% | $3.68B | Nov 14, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 2.16M | 4.16% | 4.16% | $3.03B | Nov 7, 2025 | ▲ 9.4K |
ACADIAN ASSET MANAGEMENT LLC pharmaceutical preparations | 2.07M | 3.97% | 3.97% | $2.89B | Nov 13, 2025 | — held |
STONEPINE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 1.37M | 2.63% | 2.63% | $1.92B | Nov 13, 2025 | ▲ 524.2K |
BLACKROCK, INC. pharmaceutical preparations | 1.10M | 2.12% | 2.12% | $1.55B | Nov 12, 2025 | ▼ 36.5K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
12
Increased
+1.86M shares11
New Positions
first time holders17
Decreased
−2.83M shares0
Sold Out
fully exitedNet shares change (top 50)
963.9K
+1.86M / −2.83M
Net new holders
+6
11 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PMVP insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
6
Buy transactions
1
Sell transactions
6.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Stelzer Laurie director | Jun 4, 2026 | Award | 42,000 | $1.19 | $50.0K | 42.0K | Form 4 ↗ |
LEVINE ARNOLD J director | Jun 4, 2026 | Award | 42,000 | $1.19 | $50.0K | 42.0K | Form 4 ↗ |
Gallagher Carol Giltner director | Jun 4, 2026 | Gift | 42,000 | $1.19 | $50.0K | 42.0K | Form 4 ↗ |
Gallagher Carol Giltner director | Jun 4, 2026 | Award | 42,000 | $1.19 | $50.0K | 42.0K | Form 4 ↗ |
Gallagher Carol Giltner director | Jun 4, 2026 | Gift | 42,000 | $1.19 | $50.0K | 0 | Form 4 ↗ |
FLOWERS KIRSTEN director | Jun 4, 2026 | Award | 42,000 | $1.19 | $50.0K | 42.0K | Form 4 ↗ |
BAUM CHARLES M director | Jun 4, 2026 | Award | 42,000 | $1.19 | $50.0K | 42.0K | Form 4 ↗ |
Carulli Michael Chief Financial Officer | Mar 5, 2026 | Award | 240,000 | $1.53 | $367.2K | 240.0K | Form 4 ↗ |
Ticktin Robert General Counsel & COO | Mar 5, 2026 | Award | 319,270 | $1.53 | $488.5K | 319.3K | Form 4 ↗ |
Jalota Deepika Chief Development Officer | Mar 5, 2026 | Award | 303,310 | $1.53 | $464.1K | 303.3K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
PMV Pharmaceuticals, Inc. (PMVP) is primarily owned by institutional investors, who hold approximately 70.3% of total shares outstanding. Company insiders own approximately 8.32%, while retail and public investors account for the remaining 21.38%.
The largest institutional shareholder of PMV Pharmaceuticals, Inc. is ORBIMED ADVISORS LLC, holding approximately 5.98 million shares — equal to 11.49% of outstanding shares — as of September 30, 2025.
A total of 63 institutional investors currently hold PMVP stock, with a combined institutional value of approximately $52,489,395 as of the most recent 13F filing period.
Frequently asked questions
PMVP ownershipPMV Pharmaceuticals, Inc. (PMVP) is primarily owned by institutional investors, who hold approximately 70.3% of shares. The largest shareholder is ORBIMED ADVISORS LLC with a 11.49% stake. Company insiders hold 8.32%. Data sourced from SEC Form 13F as of September 30, 2025.